Review Highlights Novel Therapeutic Strategies for Pulmonary Arterial Hypertension, Integrating Nanotechnology and Immunotherapy

Pulmonary arterial hypertension (PAH) is a devastating, progressive, and life-threatening disease characterized by severe vascular remodeling, endothelial dysfunction, and chronic inflammation within the pulmonary arteries. Despite the availability of targeted therapies that address specific pathways, long-term patient outcomes remain suboptimal, and the disease often progresses to right ventricular failure. This persistent challenge underscores an urgent need for more effective and innovative treatment strategies that can overcome the limitations of current standard-of-care approaches and offer improved prognosis for PAH patients.

This comprehensive review synthesizes recent advancements in novel therapeutic strategies for Pulmonary Arterial Hypertension (PAH). It systematically examines the integration of conventional medicine with cutting-edge approaches, including nanoparticle-mediated drug delivery systems (nano-DDS), interventions targeting the transforming growth factor beta/bone morphogenetic protein receptor type II pathway, and tyrosine kinase-based therapies. The review also delves into immunotherapies designed to modulate inflammation and correct immune imbalance, alongside emerging molecular targets such as NOTCH3/HES-5 and E-selectin. Furthermore, it discusses innovative cell-based therapies, specifically endothelial-like progenitor cell approaches, and the development of novel vaccines like ETRQβ-002.

The review highlights several promising avenues for Pulmonary Arterial Hypertension (PAH) treatment. It emphasizes that nano-DDS significantly improves drug bioavailability and targeted delivery to the pulmonary vasculature, thereby enhancing therapeutic efficacy and minimizing systemic side effects. Modulating the TGF-beta/BMPRII signaling pathway and utilizing tyrosine kinase inhibitors represent crucial strategies for reversing vascular remodeling. Immunotherapies are gaining traction by directly addressing the chronic inflammation and immune dysregulation central to PAH pathogenesis. Emerging molecular targets, including the NOTCH3/HES-5 pathway and E-selectin, offer novel points of intervention for disrupting disease progression. The review also points to the potential of regenerative approaches:

Endothelial-like progenitor cell-based cell therapy shows promise for repairing damaged endothelium and restoring vascular function, while the ETRQβ-002 vaccine represents an innovative immunomodulatory strategy. These diverse approaches collectively aim to tackle the multifaceted pathology of PAH more effectively than current monotherapies.